Hidradenitis suppurativa: a comprehensive review of pathogenetic mechanisms, clinical phenotypes, and evolving therapeutic paradigms

Authors

  • Arianna Elizabeth Jara Rios Hospital General Regional No. 2, Instituto Mexicano del Seguro Social, Cd Juarez, Chihuahua, México
  • María Magdalena Moreno Felipe Hospital General Regional No. 58, Instituto Mexicano del Seguro Social, Guanajuato, México
  • Andrea Del Carmen Diaz De La Cruz Hospital General de Zona No. 1m Instituto Mexicano del Seguro Social "Nueva Frontera", Chiapas, Mexico
  • Lizeth Montelongo Cedillo Hospital Santiago Ramon y Cajal, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Durango, Mexico

DOI:

https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20261942

Keywords:

Hidradenitis suppurativa, Acne inversa, Follicular occlusion, Interleukin-17, Tumor necrosis factor-alpha, Dysbiosis, Hurley staging, Adalimumab, Biologic therapy, Systemic comorbidity

Abstract

Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic, recurrent, and debilitating inflammatory skin condition characterized by deep-seated nodules, abscesses, fistulating sinus tracts, and scarring, primarily affecting apocrine gland-bearing skin. Historically dismissed as a disorder of poor hygiene or mere follicular occlusion, contemporary research has redefined HS as a systemic immune-mediated disease with profound implications for patient quality of life and metabolic comorbidities. This exhaustive review synthesizes the most current understanding of HS pathogenesis, which is now recognized as a multifactorial interplay of genetic predisposition, follicular hyperkeratosis and occlusion, dysbiosis of the cutaneous microbiome, and a profound dysregulation of the innate and adaptive immune system, with a prominent role for interleukin (IL)-17, IL-1β, and tumor necrosis factor-alpha (TNF-α). We meticulously detail the clinical spectrum, from prodromal manifestations to advanced Hurley stage III disease, emphasizing the nuances of phenotype classification and the critical importance of early diagnosis to mitigate disease-associated morbidity. A principal focus is dedicated to the rapidly expanding therapeutic landscape, moving beyond traditional antibiotics and surgery to include biologic agents that target specific inflammatory cytokines, with adalimumab (anti-TNF) as a cornerstone and emerging evidence for secukinumab (anti-IL-17A) and apremilast (PDE4 inhibitor). We further examine the robust association of HS with cardiometabolic syndrome, inflammatory bowel disease, and psychiatric comorbidities, advocating for a holistic, multidisciplinary management approach. This review consolidates evidence from recent clinical trials, consensus guidelines, and mechanistic studies to provide a foundational resource for clinicians and researchers navigating the complexities of this challenging disease.

Author Biography

María Magdalena Moreno Felipe, Hospital General Regional No. 58, Instituto Mexicano del Seguro Social, Guanajuato, México

.

References

Chen W, Plewig G. Should hidradenitis suppurativa/acne inversa best be renamed as “dissecting terminal hair folliculitis”? Exp Dermatol. 2017;26(6):544-7. DOI: https://doi.org/10.1111/exd.13211

Kimball AB, Kirby J, Ingram JR, Tran T, Pansar I, Ciaravino V, et al. Burden of Hidradenitis Suppurativa: A Systematic Literature Review of Patient Reported Outcomes. Dermatol Ther. 2024;14(1):83-98. DOI: https://doi.org/10.1007/s13555-023-01085-w

Shavit E, Alavi A, Bechara FG, Bennett RG, Bourcier M, Cibotti R, et al. Proceeding report of the Second Symposium on Hidradenitis Suppurativa Advances (SHSA) 2017. Exp Dermatol. 2019;28(1):94-103. DOI: https://doi.org/10.1111/exd.13849

Garg A, Kirby JS, Lavian J, Lin G, Strunk A. Sex- and Age-Adjusted Population Analysis of Prevalence Estimates for Hidradenitis Suppurativa in the United States. JAMA Dermatol. 2017;153(8):760. DOI: https://doi.org/10.1001/jamadermatol.2017.0201

Zouboulis CC, Nogueira Da Costa A, Fimmel S, Zouboulis KC. Apocrine glands are bystanders in hidradenitis suppurativa and their involvement is gender specific. J Eur Acad Dermatol Venereol. 2020;34(7):1555-63. DOI: https://doi.org/10.1111/jdv.16264

Prens E, Deckers I. Pathophysiology of hidradenitis suppurativa: An update. J Am Acad Dermatol. 2015;73(5):S8-11. DOI: https://doi.org/10.1016/j.jaad.2015.07.045

Johnston LA, Alhusayen R, Bourcier M, Delorme I, George R, O’Brien E, et al. Practical Guidelines for Managing Patients With Hidradenitis Suppurativa: An Update. J Cutan Med Surg. 2022;26:2S-24S. DOI: https://doi.org/10.1177/12034754221116115

Zouboulis CC, Benhadou F, Byrd AS, Chandran NS, Giamarellos‐Bourboulis EJ, Fabbrocini G, et al. What causes hidradenitis suppurativa?-15 years after. Exp Dermatol. 2020;29(12):1154-70. DOI: https://doi.org/10.1111/exd.14214

Ingram JR, Jenkins-Jones S, Knipe DW, Morgan CLI, Cannings-John R, Piguet V. Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa. Br J Dermatol. 2018;178(4):917-24. DOI: https://doi.org/10.1111/bjd.16101

Jfri A, Netchiporouk E, Raymond K, Litvinov IV, O’Brien E. Association of clinical severity scores with psychosocial impact in patients with hidradenitis suppurativa. J Am Acad Dermatol. 2021;84(6):1712–5. DOI: https://doi.org/10.1016/j.jaad.2020.08.022

Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol. 2010;2(1):9-16. DOI: https://doi.org/10.4161/derm.2.1.12490

Nikolakis G, Kaleta KP, Vaiopoulos AG, Wolter K, Baroud S, Wojas-Pelc A, et al. Phenotypes and Pathophysiology of Syndromic Hidradenitis Suppurativa: Different Faces of the Same Disease? A Systematic Review. Dermatology. 2021;237(5):673-97. DOI: https://doi.org/10.1159/000509873

Garg A, Neuren E, Cha D, Kirby JS, Ingram JR, Jemec GBE, et al. Evaluating patients’ unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. J Am Acad Dermatol. 2020;82(2):366-76. DOI: https://doi.org/10.1016/j.jaad.2019.06.1301

Baethge C, Goldbeck-Wood S, Mertens S. SANRA—a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019;4(1):5. DOI: https://doi.org/10.1186/s41073-019-0064-8

Nguyen TV, Damiani G, Orenstein LAV, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol. 2021;35(1):50-61. DOI: https://doi.org/10.1111/jdv.16677

Alotaibi HM. Incidence, Risk Factors, and Prognosis of Hidradenitis Suppurativa Across the Globe: Insights from the Literature. Clin Cosmet Investig Dermatol. 2023;16:545-52. DOI: https://doi.org/10.2147/CCID.S402453

Bukvić Mokos Z, Miše J, Balić A, Marinović B. Understanding the Relationship Between Smoking and Hidradenitis Suppurativa. Acta Dermatovenerol Croat ADC. 2020;28(1):9-13.

Cartron A, Driscoll MS. Comorbidities of hidradenitis suppurativa: A review of the literature. Int J Womens Dermatol. 2019;5(5):330-4. DOI: https://doi.org/10.1016/j.ijwd.2019.06.026

Jenkins T, Isaac J, Edwards A, Okoye GA. Hidradenitis Suppurativa. Dermatol Clin. 2023;41(3):471-9. DOI: https://doi.org/10.1016/j.det.2023.02.001

Downloads

Published

2026-06-22

How to Cite

Rios, A. E. J., Felipe, M. M. M., Cruz, A. D. C. D. D. L., & Cedillo, L. M. (2026). Hidradenitis suppurativa: a comprehensive review of pathogenetic mechanisms, clinical phenotypes, and evolving therapeutic paradigms. International Journal of Research in Dermatology, 12(4), 383–389. https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20261942

Issue

Section

Review Articles